Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round.

Details of the proposed CDC study have not been formally announced, but the Washington Post said the agency plans to analyze ...

Nobody complains that we have more cancer medicines available today than in the 1980s. Why should we complain about having ...

Federal support for mRNA vaccine research appears in jeopardy after KFF Health News reported Sunday that officials at the ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

The US Food and Drug Administration on Thursday issued recommendations for the composition of influenza shots for the ...

By Kushi Arora Kentucky Health News A bill that would have banned schools and workplaces from requiring a COVID-19 vaccine or ...

Idaho lawmakers are advancing a bill expanding a ban on medical mandates from public entities and businesses. The proposal ...

Researchers found no link between COVID vaccination in early pregnancy and birth defects, results show. There were also no differences in birth defect risk between either the Moderna and the ...

The measles virus is airborne and extremely contagious. Before the first measles vaccine became available in the 1960s, ...

Sensory-friendly kits aim to reduce anxiety and improve vaccination experiences for individuals with disabilities across ...

Dave Weldon was scheduled to have a confirmation hearing on Thursday, but the White House scrapped the nomination of the ...